Metastatic Prostate Cancer Market Report 2025

The metastatic prostate cancer market size has grown strongly in recent years. It will grow from $8.11 billion in 2024 to $8.81 billion in 2025 at a compound annual growth rate (CAGR) of 8.7%. The growth during the historic period can be attributed to several factors, including a growing aging population, a rising incidence of prostate cancer, increased awareness and screening programs, advancements in diagnostic techniques, and higher healthcare expenditure.

The metastatic prostate cancer market size is expected to see strong growth in the next few years. It will grow to $12.16 billion in 2029 at a compound annual growth rate (CAGR) of 8.4%. The growth during the forecast period can be attributed to factors such as expanding screening initiatives, favorable reimbursement policies, increased adoption of advanced therapies, and market expansion in emerging economies. Key trends in the forecast period include advancements in diagnostic imaging technology, innovations in targeted therapies, developments in liquid biopsy, ongoing research and development in immunotherapy, and the adoption of minimally invasive surgical techniques.

The increasing demand for personalized treatments is expected to drive the growth of the metastatic prostate cancer market. Personalized treatments are medical approaches that are customized based on an individual’s genetic profile, lifestyle, and disease characteristics to achieve more targeted and effective results. This demand is growing due to advancements in genomic profiling and biomarker testing, which help identify specific mutations and biological markers, allowing clinicians to choose therapies that are more likely to be effective for each patient. Personalized treatment strategies, such as biomarker-guided therapies and gene-targeted drugs, are revolutionizing the management of metastatic prostate cancer by matching therapies to each patient’s specific tumor profile, improving effectiveness while minimizing side effects. For instance, the Personalized Medicine Coalition reported that in 2023, the US Food and Drug Administration (FDA) approved 16 new personalized treatments for rare diseases, up from just 6 in 2022. This rising demand for personalized approaches is fueling the growth of the metastatic prostate cancer market.

Key players in the metastatic prostate cancer market are focusing on developing advanced treatments like targeted radioligand therapy to improve treatment specificity, reduce damage to healthy tissues, and enhance patient outcomes. Targeted radioligand therapy is a precision cancer treatment that combines a molecule (ligand) designed to target specific cancer cells with a radioactive isotope that delivers localized radiation to destroy those cells. For example, in March 2022, Novartis AG, a Swiss pharmaceutical company, received FDA approval for Pluvicto, the first targeted radioligand therapy for prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer. This therapy uses lutetium-177, a radioactive isotope, linked to a ligand targeting PSMA, a protein found in high levels on prostate cancer cells, enabling precise radiation delivery. Pluvicto represents a breakthrough in prostate cancer treatment, significantly extending progression-free survival in patients who have run out of other treatment options.

In June 2024, AstraZeneca PLC, a UK-based biopharmaceutical company, acquired Fusion Pharmaceuticals for $2.4 billion. With this acquisition, AstraZeneca aims to strengthen its next-generation radioconjugate platform and accelerate the development of targeted cancer therapies, particularly for metastatic castration-resistant prostate cancer and other solid tumors. Fusion Pharmaceuticals is a Canadian clinical-stage company focused on targeted therapies, including a potential treatment for metastatic castration-resistant prostate cancer (mCRPC).

Major players in the metastatic prostate cancer market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Astellas Pharma Inc., Ipsen Group, Exelixis Inc., Ferring Pharmaceuticals, Dendreon Pharmaceuticals LLC, Hinova Pharmaceuticals Inc., Janux Therapeutics Inc., Zenith Epigenetics Ltd., Tavanta Therapeutics Inc., Cardiff Oncology Inc., Oncternal Therapeutics Inc., Clarity Pharmaceuticals Ltd., and Convergent Therapeutics Inc.

North America was the largest region in the metastatic prostate cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in metastatic prostate cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the metastatic prostate cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The metastatic prostate cancer market consists of sales of radiopharmaceuticals, biosimilars, cancer pain management drugs, diagnostic imaging agents, and supportive care medications. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The metastatic prostate cancer market research report is one of a series of new reports that provides metastatic prostate cancer market statistics, including metastatic prostate cancer industry global market size, regional shares, competitors with a metastatic prostate cancer market share, detailed metastatic prostate cancer market segments, market trends and opportunities, and any further data you may need to thrive in the metastatic prostate cancer industry. This metastatic prostate cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Metastatic prostate cancer is a severe stage of prostate cancer where cancer cells have spread from the prostate gland to other areas of the body, including bones, lymph nodes, or distant organs. This stage marks the progression of the disease beyond the prostate, helping guide treatment decisions aimed at slowing the spread, relieving symptoms, and improving survival outcomes.

The primary treatment options for metastatic prostate cancer include chemotherapy, immunotherapy, hormonal therapy, radiation therapy, and other methods. Chemotherapy employs potent drugs to target and destroy fast-growing cells, including cancer cells. It can be administered through various routes, such as oral, parenteral, intravenous, intrathecal, intraperitoneal, intra-arterial, and topical. These treatments are distributed through channels like hospital pharmacies, retail pharmacies, and online platforms, and are used by end users including hospitals, clinics, cancer centers, and research laboratories.

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.